Trial Title:
The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
NCT ID:
NCT06439693
Condition:
Breast Cancer Female
Breast Cancer
Breast Cancer Metastatic
Estrogen Receptor-positive Breast Cancer
HER2-positive Breast Cancer
Stage IV Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Paclitaxel
Docetaxel
Ado-Trastuzumab Emtansine
Albumin-Bound Paclitaxel
Trastuzumab
Pertuzumab
Tucatinib
Trastuzumab deruxtecan
Conditions: Keywords:
Breast Cancer
Breast Cancer Female
Breast Cancer Metastatic
Estrogen Receptor-Positive Breast Cancer
HER2-positive Breast Cancer
Stage IV Breast Cancer
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Not yet recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Nab-Paclitaxel
Description:
Anti-microtubule agent, via intravenous (into the vein) infusion per institutional
guidelines.
Arm group label:
HER2+ Breast Cancer
Other name:
Abraxane
Other name:
ABI-007
Other name:
Albumin-bound paclitaxel
Intervention type:
Drug
Intervention name:
Paclitaxel
Description:
Anti-microtubule agent, via intravenous infusion per institutional guidelines.
Arm group label:
HER2+ Breast Cancer
Other name:
Taxol
Intervention type:
Drug
Intervention name:
Docetaxel
Description:
Anti-microtubule agent, via intravenous infusion per institutional guidelines.
Arm group label:
HER2+ Breast Cancer
Other name:
Taxotere
Intervention type:
Drug
Intervention name:
Phesgo
Description:
Pertuzumab plus trastuzumab plus hyaluronidase-zzxf, 10 or 15mL single-dose vial, via
subcutaneous (under the skin) injection per protocol.
Arm group label:
HER2+ Breast Cancer
Other name:
pertuzumab plus trastuzumab plus hyaluronidase-zzxf
Other name:
RG6264
Other name:
RO7198574
Intervention type:
Drug
Intervention name:
T-DM1
Description:
HER2-targeted antibody-drug conjugate, 16 or 100 mg single-use vials, via intravenous
infusion per institutional guidelines.
Arm group label:
HER2+ Breast Cancer
Other name:
ado-trastuzumab emtansine
Other name:
Kadcyla
Intervention type:
Drug
Intervention name:
Pertuzumab
Description:
Recombinant humanized monoclonal antibody, 20mL single-use vial, via intravenous infusion
per institutional guidelines.
Arm group label:
HER2+ Breast Cancer
Intervention type:
Drug
Intervention name:
Trastuzumab Deruxtecan
Description:
HER2-directed antibody drug conjugate, 100mg vial, via intravenous infusion per
institutional guidelines.
Arm group label:
HER2+ Breast Cancer
Other name:
Enhertu
Other name:
fam-trastuzumab deruxtecan-nxki
Other name:
T-DXd
Other name:
DS-8201a
Intervention type:
Drug
Intervention name:
Trastuzumab Subcutaneous Subcutaneous
Description:
Humanized IgG1 kappa monoclonal antibody, 6mL vial, via subcutaneous injection per
institutional guidelines.
Arm group label:
HER2+ Breast Cancer
Other name:
Herceptin Hylecta
Other name:
Trastuzumab and hyaluronidase-oysk
Intervention type:
Drug
Intervention name:
Tucatinib
Description:
Tyrosine Kinase HER2 Inhibitor, 50 or 150mg tablet taken orally per institutional
guidelines.
Arm group label:
HER2+ Breast Cancer
Intervention type:
Drug
Intervention name:
Trastuzumab
Description:
Humanized IgG1 kappa monoclonal antibody, 150 mg single-dose vial, via intravenous
infusion per institutional guidelines.
Arm group label:
HER2+ Breast Cancer
Summary:
The purpose of this study is to test the safety and effectiveness of a sequence of drugs
(a Taxane plus Trastuzumab plus Pertuzumab followed by Trastuzumab Deruxtecan, followed
by Tucatinib plus Ado-Trastuzumab Emtansine (T-DM1), followed by Trastuzumab plus
Pertuzumab plus Tucatinib) in HER2+ Breast Cancer. The study will help investigators
understand whether first intensifying therapy for a specific period and then stopping
treatment is safe and effective for participants.
The names of the study drugs involved in this study are:
- Paclitaxel (a type of anti-microtubule agent)
- Docetaxel (a type of anti-microtubule agent)
- Nab-Paclitaxel (a type of anti-microtubule agent)
- Trastuzumab (a type of IgG1 kappa monoclonal antibody)
- Pertuzumab (a type of monoclonal antibody)
- Trastuzumab Deruxtecan (a type of HER2-directed antibody drug conjugate)
- Tucatinib (Tyrosine Kinase HER2 Inhibitor)
- Ado-trastuzumab emtansine or T-DM1 (a type of HER2-targeted antibody-drug conjugate)
Detailed description:
This is an open-label phase II single-arm study to test the efficacy of a regimen of
human epidermal growth factor receptor 2 (HER2)-targeted study drugs in participants with
HER2-Positive metastatic Breast Cancer (HER2+ MBC).
The U.S. Food and Drug Administration (FDA) has approved all the study drugs as a
treatment option for metastatic, HER2+ breast cancer. In this study, investigators are
planning to give a series of treatments in a row without waiting for disease worsening
and then stopping HER2 treatment.
The research study procedures include screening for eligibility, study treatment visits,
blood tests, tumor biopsies, questionnaires, Computed Tomography (CT) scans, Magnetic
Resonance Imaging (MRI) scans, echocardiograms, and electrocardiograms.
Participation in this research study is expected to last about 93 weeks (12 weeks for
Part A, 18 weeks for Part B, 12 weeks for Part C, and 51 weeks for Part D) for study
treatment and approximately three months to ten years for follow up.
It is expected that about 72 people will take part in this research study.
Seagen Inc. is supporting this study by providing the study drug, tucatinib, and funding.
Criteria for eligibility:
Criteria:
Inclusion criteria:
- Participants must have histologically or cytologically confirmed unresectable
locally advanced or metastatic invasive breast carcinoma. Patients must have stage
IV breast carcinoma at diagnosis (i.e., de novo metastatic) with unequivocal
evidence of metastasis on imaging.
- Diagnosis of HER2-positive invasive breast carcinoma and 3+ by immunohistochemistry
on both breast and metastatic biopsies, as defined by the current American Society
of Clinical Oncology - College of American Pathologists (ASCO/CAP) guidelines. HER2
status must be determined at a Clinical Laboratory Improvements Amendments
(CLIA)-certified or International Organization for Standardization (ISO)-accredited
laboratory (central testing not required). Patients with HER2 1+ or 2+ disease which
is HER2 FISH positive are not eligible to enroll.
- No prior systemic therapy for invasive breast cancer, aside from first-line
trastuzumab/pertuzumab/taxane (THP) within 6 weeks from treatment start. Prior
endocrine therapy for non-invasive breast carcinoma or non-cancerous lesions is
allowed if it has been completed at least 5 years prior to study entry.
- Age ≥18 years. Because no dosing or adverse event data are currently available on
the use of trastuzumab, pertuzumab, paclitaxel, trastuzumab deruxtecan, T-DM1 and
tucatinib in Participants <18 years of age, children are excluded from this
study, but will be eligible for future pediatric trials.
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1
- Left ventricular ejection fraction (LVEF) ≥50%, as assessed by echocardiogram (ECHO)
or multiple-gated acquisition scan (MUGA) documented within 12 weeks prior to first
dose of study treatment, or within 12 weeks before starting THP for patients who
start metastatic therapy prior to study entry.
- Participants must meet the following organ and marrow function as defined below
within 28 days prior to registration:
- Hgb ≥9.0 g/dL
- Absolute Neutrophil Count ≥ 1,000 /mm3
- Platelets ≥100,000/mm3
- Total bilirubin ≤ 1.5 x ULN (institutional) or direct bilirubin within normal
limits in patients with a history of Gilbert's syndrome.
- AST and ALT ≤ 2.5 x ULN (institutional) or ≤ 5 x ULN for participants with
documented liver metastases
- Serum creatinine ≤ 1.5 x ULN (institutional) OR calculated GFR ≥60mL/min
- Participants with concurrent human immunodeficiency virus (HIV) infection are
eligible provided the following criteria are met:
- CD4+ T-cell (CD4+) counts > 350 cells/uL
- No history of AIDS-defining opportunistic infection within 12 months prior to
enrollments
- Any medication used in an ART regimen must have no known interaction with the
agents used in the study treatment regimen.
- Participants with active or chronic Hepatitis B or C are eligible provided they meet
the liver function criteria described in 3.1.7 and are not on a medication with a
known liver function criteria described in 3.1.7 and are not on a medication with a
known interaction with the agents used in the study treatment regimen. The following
guidance applies:
- patients with chronic HBV infection with active disease who meet the FDA
criteria for anti-HBV therapy should be on a suppressive antiviral therapy
prior to initiation of cancer therapy.
- patients with a history of HCV infection should have completed curative
antiviral treatment. HCV viral load must be below the limit of quantification.
- patients who are HCV Ab positive but HCV RNA negative due to prior treatment or
natural resolution are eligible.
- Participants with brain metastases identified at diagnosis or at time of screening
are eligible if the following criteria are met:
- Known, untreated brain metastases must undergo definitive local therapy - as
determined by treating physician - prior to study entry.
- Treated brain metastases must be clinically stable since treatment. Restaging
brain MRI is not required to deem eligibility if local therapy was given within
28 days from first dose of study treatment. Patients are eligible if time from
local therapy and first dose of study treatment is:
- 7 days for stereotactic radiosurgery (SRS);
- 14 days for whole-brain radiation therapy (WBRT);
- 28 days for surgical resection.
- Patients who have already started THP prior to study entry and have brain
metastasis detected at screening MRI are eligible after completion of
definitive local therapy- as determined by treating physician. Systemic
treatment can be interrupted as determined by the treating physician and after
discussion with the Sponsor Investigator.
- Participants with a prior or concurrent malignancy whose natural history or
treatment does not have the potential to interfere with the safety or efficacy
assessment of the investigational regimen are eligible (i.e., adequately treated
carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate
cancer, ductal carcinoma in situ, or Stage I uterine cancer).
- This study involves agents that have known genotoxic, mutagenic and teratogenic
effects. For this reason, women of child-bearing potential and men must agree to use
adequate contraception (hormonal or barrier method of birth control; abstinence)
prior to study entry and for the duration of study participation. Should a woman
become pregnant or suspect she is pregnant while she or her Partner is participating
in this study, she should inform her treating physician immediately. Men treated or
enrolled on this protocol must also agree to use adequate contraception prior to the
study, for the duration of study participation, and 7 months after completion of
study therapy.
- Women of childbearing potential must have had a negative pregnancy test within 14
days of registration. Childbearing potential is defined as: those who have not been
surgically sterilized and/or have had a menstrual period in the past 12 months or
who have been on ovarian suppression in the past year.
- Ability to understand and the willingness to sign a written informed consent
document indicating awareness of the investigational nature and the risks of this
study
- Willingness and ability to comply with scheduled visits, treatment plan, laboratory
tests, and other study procedures.
Exclusion criteria:
- Prior history of invasive breast carcinoma
- Treatment with any other investigational agents for this condition.
- Major surgical procedure (excluding placement of vascular access) or significant
traumatic injury within 28 days of study entry or an anticipated need for major
surgery during the study.
- Extracranial palliative radiotherapy within 7 days prior to enrollment.
- History of allergic reactions attributed to compounds of similar chemical or
biologic composition to trastuzumab, pertuzumab, paclitaxel, trastuzumab deruxtecan,
trastuzumab emtansine, tucatinib.
- Participants with a medical history of myocardial infarction within 6 months before
enrollment or symptomatic CHF (NYHA Class II to IV).
- Subjects must not have any of the following:
- Any untreated brain lesion on screening MRI, unless approved by the Sponsor
Investigator
- Ongoing use of systemic corticosteroids for control of symptoms of brain
metastases at a total daily dose of >2 mg of dexamethasone (or equivalent).
- Known or concurrent leptomeningeal disease on screening MRI
- Poorly controlled (>1/week) generalized or complex partial seizures
- History of arrhythmia (multifocal premature ventricular contractions, bigeminy,
trigeminy, ventricular tachycardia), which is symptomatic or requires treatment
(CTCAE Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment,
or asymptomatic sustained ventricular tachycardia. Participants with atrial
fibrillation controlled by medication or arrhythmias controlled by pacemakers may be
permitted upon discussion with the Sponsor-Investigator.
- History of (non-infectious) ILD/pneumonitis that required steroids, has current
ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging
at screening.
- History of other lung disease, such as:
- Lung-specific intercurrent clinically significant illnesses including, but not
limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within 3
months of study enrolment, severe asthma, severe chronic obstructive pulmonary
disorder (COPD), restrictive lung disease, pleural effusion etc.).
- Any autoimmune, connective tissue or inflammatory disorders (e.g., rheumatoid
arthritis, Sjogren's, sarcoidosis, etc.) where there is documented, or a
suspicion of pulmonary involvement at the time of screening.
- Prior pneumonectomy.
- Active or uncontrolled clinically serious infection
- Have inability to swallow pills or significant gastrointestinal disease which would
preclude the adequate oral absorption of medications
- Have ongoing ≥ Grade 2 diarrhea of any etiology
- Participants receiving any medications or substances that are inhibitors or inducers
of CYP2C8 and/or CYP3A4 are ineligible. Because the lists of these agents are
constantly changing, it is important to regularly consult a frequently updated
medical reference.
- Pregnant women are excluded from this study because of potential for teratogenic or
abortifacient effects of study drugs. Because there is an unknown but potential risk
for adverse events in nursing infants secondary to treatment of the mother with
study drugs, breastfeeding should be discontinued prior to enrollment.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Dana-Farber Cancer Institute
Address:
City:
Boston
Zip:
02215
Country:
United States
Contact:
Last name:
Heather Parsons, MD, MPD
Phone:
617-632-3800
Email:
HeatherA_parsons@dfci.Harvard.edu
Investigator:
Last name:
Heather Parsons, MD, MPH
Email:
Principal Investigator
Start date:
November 2024
Completion date:
March 30, 2033
Lead sponsor:
Agency:
Dana-Farber Cancer Institute
Agency class:
Other
Collaborator:
Agency:
Translational Breast Cancer Research Consortium
Agency class:
Other
Collaborator:
Agency:
Johns Hopkins University
Agency class:
Other
Source:
Dana-Farber Cancer Institute
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06439693
